Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Pathway 1 (patients hospitalized with acute heart failure)~1. Age \>18 years~2. Willingness and ability to provide informed consent~3. Hospitalization for AHF with at least 1 symptom (dyspnea, orthopnea, or edema) AND 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion on chest radiography, BNP \> 250 ng/mL or NTproBNP \> 1000 ng/mL) of congestion~4. Persistent congestion defined by the presence of at least 2 or more of the following at the time of consent:~   1. Peripheral edema~  2. Rales~  3. Elevated JVP~  4. Ascites~  5. BNP \> 250 ng/mL or NTproBNP \> 1000 ng/mL during index hospitalization~  6. Orthopnea~5. Total anticipated daily IV furosemide dose (at time of screening) \>80-240 mg (or equivalent)/day~6. Anticipated need for at least 24 more hours of parenteral diuretic therapy~Exclusion Criteria for Pathway 1~1. Severe renal dysfunction (eGFR\< 20 ml/min/1.73m2) within 24 hours of enrollment~2. Requirement for inotropes (other than digoxin) or mechanical support during hospitalization~3. Clinically significant electrical instability during hospitalization~4. Anticipated need for ongoing intravenous therapies beyond diuretics (electrolyte repletion, vasodilators, antibiotics, etc.)~5. Planned discharge to location other than home (e.g., hospice, skilled nursing facility, etc.)~6. Anticipated cardiac transplantation or left ventricular assist device within the next 30 days~7. Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade~8. Known or anticipated pregnancy in the next 30 days~9. Prior use of a subcutaneous furosemide pump or current use of any subcutaneous pump, on-body infusion devices or patients who give regimented injections at the intended site of the furosemide infusion device.~10. Other psychosocial or physical barriers to following the protocol and using SQ pump device outside the hospital setting~11. Known allergy to furosemide~12. Known sensitivity or allergy to medical adhesive tape~13. Enrollment or planned enrollment in another therapeutic clinical trial in next 3 months~14. Presentation is for indication other than CHF~Inclusion Criteria for Pathway 2 (Outpatients with heart failure presenting with volume overload necessitating treatment with parenteral loop diuretics)~1. Age \>18 years~2. Willingness and ability to provide informed consent~3. HF now presenting with volume overload defined by the presence of at least 2 or more of the following at the time of consent:~   1. Peripheral edema~  2. Rales~  3. Elevated JVP~  4. Ascites~  5. BNP \> 250 ng/mL or NTproBNP \> 1000 ng/mL during this episode of decompensation~  6. Orthopnea~4. Need for parenteral furosemide with an estimated SQ furosemide requirement between 80-240 mg/day~5. Anticipated need for at least 24 hours of parenteral diuretic therapy~Exclusion Criteria for Pathway 2~1. Severe renal dysfunction (eGFR\< 20 ml/min/1.73m2) within 24 hours of enrollment~2. Anticipated need for inotropes (other than digoxin) or mechanical support to treat current episode of decompensation~3. Clinically significant electrical instability requiring hospitalization~4. Anticipated need for ongoing intravenous therapies beyond diuretics (electrolyte repletion, vasodilators, antibiotics, etc.)~5. Residence at location other than home (e.g., hospice, skilled nursing facility, etc.)~6. Anticipated cardiac transplantation or left ventricular assist device within the next 30 days~7. Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade~8. Known or anticipated pregnancy in the next 30 days~9. Prior use of a subcutaneous furosemide pump or current use of any subcutaneous pump, on-body infusion devices or patients who give regimented injections at the intended site of the furosemide infusion device.~10. Other psychosocial or physical barriers to following the protocol and using SQ pump device outside the hospital setting~11. Known allergy to furosemide~12. Known sensitivity or allergy to medical adhesive tape~13. Enrollment or planned enrollment in another therapeutic clinical trial in next 3 months.~14. Presentation is for indication other than CHF.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous Furosemide and sc2wear device (Type: EXPERIMENTAL): Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
- Usual Care (Type: NO_INTERVENTION): Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).